Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Rhabdomyosarcoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Gliosarcoma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 4Radiotherapy 3Cyclophosphamide 3Carmustine 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3sargramostim 2aldesleukin 2Thalidomide 2Paclitaxel 2Gadolinium DTPA 2Filgrastim 2Donepezil 2Biopsy 2temsirolimus 1surufatinib 1plerixafor 1omburtamab I-131 1ganitumab 1gallium Ga 68 dotatate 1gadobutrol 1gadobenic acid 1entinostat 1cixutumumab 1carboxyamido-triazole 1azurin (50-77) 1antineoplaston AS 2-1 1antineoplaston A10 1adavosertib 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × adavosertib × Sarcoma × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡